Qinhuangdao Zizhu Pharmaceutical Co Ltd (China) has reason to celebrate:
The company manufactures ethinylestradiol, which was recently prequalified by the WHO Prequalification of Medicines Programme (PQP) under its API (active pharmaceutical ingredient) prequalification procedure. This is the first API prequalified in the therapeutic area of Reproductive Health.
Qinhuangdao Zizhu has been supported throughout the process by technical experts and staff of another Coalition member, the Concept Foundation, under the RHSC’s Quality of Reproductive Health Medicines (QuRHM) programme. High-quality APIs are vital to the production of high-quality medicines and ethinylestradiol is one of the main ingredients used in the manufacture of the most commonly used combined oral contraceptive (COC) pills.